Metraipolis › archive › dc_d7bce5f19bee

Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial — Europe PMC PMID:42205598

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42205598
DOI
10.1093/ofid/ofag277
License (as archived)
solo-consultazione
Archived
2026-11-02T08:54:36.260Z
SHA-256 of the archived text
d2a68dc5e53bd45ae37fabeb96ebe6d4215317ea482dcd230fe0fb4dd1273bab
Stable URL of this page
https://metraipolis.com/documento/dc_d7bce5f19bee

How to cite

Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial — Europe PMC PMID:42205598 — Europe PMC (en), https://europepmc.org/article/MED/42205598 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d7bce5f19bee (Metraipolis archive dc_d7bce5f19bee, sha256 d2a68dc5e53bd45ae37fabeb96ebe6d4215317ea482dcd230fe0fb4dd1273bab)
BibTeX
@misc{dcd7bce5f19bee,
  title = {Safety and Immunogenicity of a Vaccine Against Coxsackieviruses B (PRV-101)-Follow-up of the First-in-Human Phase 1 Trial — Europe PMC PMID:42205598},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42205598},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d7bce5f19bee; sha256 d2a68dc5e53bd45ae37fabeb96ebe6d4215317ea482dcd230fe0fb4dd1273bab},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42205598. Agents can read the archived copy with the MCP tool read_document.